ASDS 2024: new phase III READY-4 data demonstrate long-term safety and efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™) Press release
EADV 2024 Late breaking news sessions: new Galderma data demonstrating nemolizumab’s long-term efficacy and safety in atopic dermatitis and durability in prurigo nodularis to be shared during three oral presentations Press release
Phase III Arcadia 1 and 2 trial primary results published in The Lancet: Galderma’s nemolizumab improves key aspects of atopic dermatitis – itch, skin lesions and sleep disturbance Press release
Galderma granted key manufacturing license updates for new biologics capabilities at its center of excellence Press release
Galderma launches Restylane® Volyme™ in China – one of the world’s fastest growing aesthetics markets Press release
Galderma receives filing acceptances for nemolizumab in prurigo nodularis and atopic dermatitis in four additional countries Press release
Galderma prices IPO at CHF 53 per share and will start trading on the SIX Swiss Exchange tomorrow Press release